Is Now The Time To Look At Buying Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD)?
While Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) might not have the largest market cap around , it saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$12.73 and falling to the lows of US$10.76. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Great Lakes Dredge & Dock's current trading price of US$11.00 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Great Lakes Dredge & Dock's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
See our latest analysis for Great Lakes Dredge & Dock
Great news for investors – Great Lakes Dredge & Dock is still trading at a fairly cheap price according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. we find that Great Lakes Dredge & Dock's ratio of 12.52x is below its peer average of 29.65x, which indicates the stock is trading at a lower price compared to the Construction industry. However, given that Great Lakes Dredge & Dock's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. Though in the case of Great Lakes Dredge & Dock, it is expected to deliver a relatively unexciting earnings growth of 7.9%, which doesn't help build up its investment thesis. Growth doesn't appear to be a main reason for a buy decision for the company, at least in the near term.
Are you a shareholder? Even though growth is relatively muted, since GLDD is currently trading below the industry PE ratio, it may be a great time to accumulate more of your holdings in the stock. However, there are also other factors such as financial health to consider, which could explain the current price multiple.
Are you a potential investor? If you've been keeping an eye on GLDD for a while, now might be the time to enter the stock. Its future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy GLDD. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed assessment.
If you'd like to know more about Great Lakes Dredge & Dock as a business, it's important to be aware of any risks it's facing. For example - Great Lakes Dredge & Dock has 1 warning sign we think you should be aware of.
If you are no longer interested in Great Lakes Dredge & Dock, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
16 minutes ago
- Associated Press
ABL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Abacus Global Management, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Abacus Global operates as an alternative asset manager and market maker. THE REVELATION: On June 4, 2025, Morpheus Research published a report titled 'Abacus Global Management: This $740 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die.' On this news, Abacus Global's stock price fell more than 21%. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Yahoo
21 minutes ago
- Yahoo
Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers
Qualcomm Inc (NASDAQ:QCOM) announced on Monday that it has agreed to acquire semiconductor company Alphawave IP Group Plc for approximately $2.4 billion in cash. The purchase price implies 183 pence per share for Alphawave, implying close to a 96% premium to the price immediately before Qualcomm disclosed its interest in the company. The acquisition of Alphawave Semi aims to further accelerate, and provide key assets for, Qualcomm's expansion into data centers. Qualcomm Oryon CPU and Hexagon NPU processors are well positioned to meet the growing demand for high-performance, low-power computing, which is being driven by a rapid increase in AI inferencing and the transition to custom CPUs in data centers, the company said in a press release. Also Read: The deal, subject to regulatory and shareholder approval, will likely close in the first quarter of 2026. Qualcomm held $13.85 billion in cash and equivalents as of March 31, 2025. In May, JP Morgan analyst Samik Chatterjee said Alphawave has higher strategic importance for Qualcomm, which has recently more explicitly outlined its intent to pursue the data center market as another pillar of growth and diversification. The analyst said Alphawave's acquisition and capabilities regarding data center connectivity IP would complement its earlier acquisition of Nuvia and its capabilities for designing data center CPUs and AI inference chips based on custom ARM cores. Chatterjee expects Alphawave's breadth of capabilities to add to Qualcomm's portfolio, positioning the company to benefit from tailwinds related to strong growth in Custom silicon and ASIC adoption within AI infrastructure and development in content about connectivity products within AI data centers. He added that Alphawave's immediate contribution to Qualcomm's financial performance is unlikely material, but the company expects synergies from its entry into the broader data center TAM. Price Action: QCOM stock is trading higher by 0.19% to $149.52 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? QUALCOMM (QCOM): Free Stock Analysis Report This article Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Nutraceutical Excipients Global Strategic Business Report 2025-2030: Technological Innovations in Multi-Functional Excipients Propel Growth, Increasing Preference for Clean-Label and Natural Ingredients
The global Nutraceutical Excipients market is expected to grow from USD 5 billion in 2024 to USD 7.2 billion by 2030, at a CAGR of 6.2%. Key trends driving this market include a shift towards clean-label, organic excipients and technological advances like nanotechnology that enhance ingredient bioavailability. This report offers comprehensive insights into market trends, regional growth projections, and strategic opportunities, identifying major players such as ABF Ingredients and Cargill. Explore detailed regional analyses and future market insights to inform strategic decisions. Nutraceutical Excipients Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Nutraceutical Excipients - Global Strategic Business Report" report has been added to global market for Nutraceutical Excipients was valued at US$5.0 Billion in 2024 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Nutraceutical excipients are inactive ingredients used in the production of nutraceutical products such as dietary supplements, functional foods, and fortified beverages. These excipients serve a crucial role by aiding in the stabilization, preservation, and delivery of active ingredients like vitamins, minerals, and bioactive compounds. Growth in the Nutraceutical Excipients Market Is Driven by Several FactorsGrowth in the nutraceutical excipients market is driven by several factors, including innovations in excipient technology, evolving consumer preferences, and increasing regulatory scrutiny. Advances in excipient formulations, such as the development of multifunctional and bioenhancing excipients, are expanding the range of nutraceutical products available to consumers. The growing popularity of clean-label and organic products is also fueling demand for natural excipients that meet consumer expectations for purity and safety. Additionally, the rise in chronic health conditions and aging populations is increasing the need for functional and targeted nutraceuticals, further driving demand for excipients that improve the bioavailability and stability of active ingredients. Regulatory requirements for product safety and quality are pushing manufacturers to innovate, ensuring excipients meet the highest standards for efficacy and safety. How Are Innovations in Nutraceutical Excipients Shaping the Market?Technological advancements in excipient development are driving significant changes in the nutraceutical market. The demand for excipients that are organic, non-GMO, and free from allergens is on the rise, reflecting consumer preferences for clean-label products. New innovations in multifunctional excipients, which can perform multiple roles such as improving both bioavailability and stability, are gaining traction. Additionally, advancements in nanotechnology are enabling the development of excipients that enhance the solubility and absorption of poorly soluble nutraceutical ingredients. These innovations are leading to the production of more effective, faster-acting, and longer-lasting nutraceutical products, appealing to consumers who prioritize both efficacy and natural Are Consumer Preferences and Regulatory Trends Impacting Demand for Nutraceutical Excipients?The growing focus on health and wellness has spurred consumer demand for nutraceutical products that are safe, effective, and free from artificial additives. This shift is influencing the nutraceutical excipients market, as manufacturers are increasingly opting for natural, organic, and clean-label excipients that align with consumer values. Regulatory bodies are also playing a key role by setting stringent guidelines for excipient safety and quality, particularly in regions like North America and Europe. As a result, excipient manufacturers are investing in research and development to create products that comply with these regulations while offering superior functionality. Moreover, the rise of personalized nutrition is driving demand for excipients that enable the production of customized nutraceutical solutions, expanding the market's Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as ABF Ingredients, Cargill, Inc., Dow, Inc., DuPont de Nemours, Inc., EGGLE Wasserburg Verwaltungs GmbH and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Binders segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 7.6%. The Fillers & Diluents segment is also set to grow at 5.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments: Functionality (Binders, Fillers & Diluents, Coating Agents, Lubricants, Disintegrants, Flavoring Agents) Form (Dry, Liquid) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 308 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5 Billion Forecasted Market Value (USD) by 2030 $7.2 Billion Compound Annual Growth Rate 6.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Nutraceutical Excipients - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Consumer Demand for Functional Foods and Dietary Supplements Drives Growth in Nutraceutical Excipients Market Technological Advancements in Drug Delivery Systems Propel the Adoption of Innovative Nutraceutical Excipients Increasing Preference for Clean-Label and Natural Ingredients Expands the Market for Organic Nutraceutical Excipients Growing Focus on Enhanced Bioavailability and Solubility Strengthens Demand for Advanced Excipient Formulations Rising Awareness of Preventative Healthcare and Wellness Fuels Growth in Nutraceutical Supplements, Driving Excipient Demand Technological Innovations in Multi-Functional Excipients Propel Growth in Nutraceutical Manufacturing Efficiency Increased Regulatory Scrutiny on Ingredient Safety and Quality Standards Spurs Demand for Compliant Excipients Growing Use of Probiotics and Prebiotics Expands Opportunities for Specialized Nutraceutical Excipients Consumer Trends Toward Sugar-Free and Low-Calorie Supplements Accelerate Demand for Sweetening and Flavoring Excipients Expansion of Sports Nutrition and Weight Management Products Throws the Spotlight on Performance-Enhancing Excipients Rising Popularity of Plant-Based and Vegan Nutraceuticals Strengthens the Business Case for Non-Animal Derived Excipients Growth in Elderly Population and Demand for Age-Related Supplements Propel Market Adoption of Digestive-Friendly Excipients FOCUS ON SELECT PLAYERS ABF Ingredients Cargill, Inc. Dow, Inc. DuPont de Nemours, Inc. EGGLE Wasserburg Verwaltungs GmbH Hilmar Ingredients IMCD Group BV Ingredion, Inc. Innophos Holdings, Inc. Jrs Pharma GmbH Co. KG Kerry Group plc Roquette Freres S.A. Sensient Pharmaceutical For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Nutraceutical Excipients Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
